drugset / Trial / NCT01829048

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

NCT01829048

Phase 1 Completed 37 enrolled Pfizer
RandomizedDouble-blindBasic science

Summary

To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.

Timeline

Start
2013-03-06
Primary completion
2013-10-17
Completion
2013-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject MARDEPODECT Small molecule 15 mg Oral

Indications